Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-10
2011-05-10
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
07939263
ABSTRACT:
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan
patent: 4109496 (1978-08-01), Allemann
patent: 4323546 (1982-04-01), Crockford
patent: 4873191 (1989-10-01), Wagner
patent: 4968103 (1990-11-01), McNab
patent: 4981785 (1991-01-01), Nayak
patent: 5034506 (1991-07-01), Summerton
patent: 5223409 (1993-06-01), Ladner
patent: 5225539 (1993-07-01), Winter
patent: 5283317 (1994-02-01), Saifer
patent: 5358691 (1994-10-01), Clark
patent: 5489677 (1996-02-01), Sanghvi
patent: 5538848 (1996-07-01), Livak
patent: 5539082 (1996-07-01), Nielsen
patent: 5565332 (1996-10-01), Hoogenboom
patent: 5585089 (1996-12-01), Queen
patent: 5599677 (1997-02-01), Dowell
patent: 5602240 (1997-02-01), de Mesmaeker
patent: 5614396 (1997-03-01), Bradley
patent: 5631169 (1997-05-01), Lakowicz
patent: 5639606 (1997-06-01), Willey
patent: 5643765 (1997-07-01), Willey
patent: 5705188 (1998-01-01), Yano
patent: 5714331 (1998-02-01), Buchardt
patent: 5719262 (1998-02-01), Buchardt
patent: 5824544 (1998-10-01), Armentano
patent: 5830730 (1998-11-01), German
patent: 5872154 (1999-02-01), Wilson et al.
patent: 5876978 (1999-03-01), Willey
patent: 5885530 (1999-03-01), Babson
patent: 5885808 (1999-03-01), Spooner
patent: 5981225 (1999-11-01), Kochanek
patent: 5994106 (1999-11-01), Kovesdi
patent: 5994128 (1999-11-01), Fallaux
patent: 5994132 (1999-11-01), Chamberlain
patent: 6001557 (1999-12-01), Wilson et al.
patent: 6004528 (1999-12-01), Bergstein
patent: 6019978 (2000-02-01), Ertl
patent: 6033908 (2000-03-01), Merigan
patent: 6054297 (2000-04-01), Carter
patent: 6080912 (2000-06-01), Bremel et al.
patent: 6159750 (2000-12-01), Edmonds
patent: 6180370 (2001-01-01), Queen
patent: 6198107 (2001-03-01), Seville
patent: 6506559 (2003-01-01), Fire
patent: 6984522 (2006-01-01), Clarke
patent: WO/90/08832 (1990-08-01), None
patent: WO/94/10300 (1994-05-01), None
patent: WO/97/30731 (1997-08-01), None
patent: WO/99/02685 (1999-01-01), None
patent: WO/00/09675 (2000-02-01), None
patent: WO/00/12738 (2000-03-01), None
patent: WO/02/12447 (2002-02-01), None
patent: WO/03/050502 (2003-06-01), None
patent: 2005/005601 (2005-01-01), None
patent: 2006/138275 (2006-12-01), None
US 5,962,233, 10/1999, Livak (withdrawn)
Yoshida et al (Int J Oncology, Mar. 2001, 18(3): abstract).
Gossler et al. “Transgenesis by means of blastocyst-derived embryonic stem cell lines” Proc. Acad. Sci. USA vol. 83, 1986, p. 9065-9.
Greene et al., 1998, Eur. J. Neurosci. Greene et al., 1998, Eur. J. Neurosci. vol. 10 pp. 1911-1925 Identification and characterization of a novel member of the fibroblast growth factor family.
Griffin et al., “Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer” J Clin Oncol. Apr. 1991;9(4):631-40.
Hage, et al. “Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions” J. Chromatogr. Biomed. Sci. Appl vol. 699, 1997, pp. 499-525.
Hamacher et al.,2004, Dtsch. Med vol. 129pp. 1976-1980.
Hamburger, et al. “Primary Bioassay of Human Tumor Stem Cells,” Science (Jul. 229, 1977) 197 (4302): 461-3.
Hanahan, et al. 'The hallmarks of cancer' CELL vol. 100, 2000, pp. 57-70.
Harris et al., 1991, Breast Diseases, Lippencott.
Hartigan, 1975, Clustering Algorithms, vol. xiii pp. 351.
Haskell, et al. “Efficient production of transgenic cattle by retroviral infection of early embryos” Mol. Reprod. Dev. vol. 40, 1995, p. 386-90.
Hazan et al., “Cadherin Switch in Tumor Progression,” Annals NY Acad Science bol 1014, pp. 155-163 (2004).
Hedegpeth et al, “Regulation of Glycogen Synthase Kinase 3 and Downstream Wnt Signaling by Axin,” Molecular and Cellular Biol, vol. 19, pp. 7147-7157 (1997).
“Hedgepeth et al., 1999, Mol Cell Biol. vol. 19 pp. 7147-57Regulation of Glycogen Synthase Kinase 3b and DownstreamWnt Signaling by Axin ”.
Heegaard “Capillary electrophoresis for the study of affinity interactions” J. Mol. Recognit vol. 11, 1998, pp. 141-148.
Heppner, “Tumor Heterogeneity,” Cancer Research vol. 44, pp. 2259-65 (1984).
Herbert et al, “Molecular physiology of cation-coupled CI-cotransport: the SLC12 family” Pglugers Arch. European J Physiology vol. 447, pp. 580-593 (2004).
“Hillier et al., 1996, GenResvol. 6pp. 807-828 Generation and Analysis of 280,000 HumanExpressed Sequence Tags”.
Hnatowich et al., “The preparation and labeling of DTPA-coupled albumin” Int. J Appl. Radiat. lot. vol. 33, 1982, p. 327-32.
Hoffman, 1999, Invest New Drugs vol. 17pp. 343-359 Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.
Hogan et al.: ‘Manipulating the Mouse Embryo’, 1986, Cold Spring Harbor Laboratory Press.
Holen et al. “Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor” Nucleic Acids Res. vol. 30, 2002, pp. 1757-1766.
Hong et al., 2001, genesis vol. 29 pp. 163-171 The winged helix/forkhead transcription factor Foxq1 regulates differentiation of hair in satin mice.
Houghten “The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides” Biotechniques vol. 13, 1992, pp. 412-421.
Howes et al, “Cationic Trypsingen Mutations and Pancreatitis” Clin Lab Med, vol. 25, pp. 39-59 (2005).
“Hughes et al., 2002. Mol Ther. vol. 5 pp. 16-24 Viral-Mediated Gene Transfer to Mouse PrimaryNeural Progenitor Cells”.
Ikeda et al., 1993, Exp. Hematol vol. 21 pp. 1686-1694 Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor.
Imatani, A. & Callahan, R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 19,223-231 (2000).
Iwabuchi et al. “Use of the two-hybrid system to identify the domain of p53 involved in oligomerization” Oncogene vol. 8, 1993, pp. 1693-1696.
Jaenisch “Transgenic animals” Science vol. 240, 1988, p. 1468-74.
“Jaenisch 1976, PNAS vol. 73pp. 1260 Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus(in vitro infection of 4-8 cell embryos with exogenous Moloney leukemia virus/leukemia/genetic transmission/DNA annea”.
Jahner et al. “Insertion of the bacterial gpt gene into the germ line of mice by retroviral infection” Proc. Natl. Acad Sci. USA vol. 82, 1985, p. 6927-31.
Jahner et al. “De novo methylation and expression of retroviral genomes during mouse embryogenesis” Nature vol. 298, 1982, p. 623-8.
Jehn, et al. “Cutting edge: protective effects of notch-1 on TCR-induced apoptosis” J Immunol., 162(2):635-8 (1999).
Jette et al, “The Tumor Supressor Adenomatous Polyposis Coli and Caudal Related Homeodomain Protein Regulate Expression of Retinol Gehydrohenase L” J. Biol Chem vol. 279, pp. 34397-405 (2004).
Jonsson, M., Borg, A., Nilbert, M. & Andersson, T. Involvement of adenomatopolyposis coli (APC)/beta-catenin signalling in human br˜ast cancer. Eur J Cancer 36, 242-8 (2000).
Kawano & Kypta, 2003, J Cell Sci. vol. 116 pp. 2527-34 Secreted antagonists of the Wnt signalling pathway.
Clarke Michael F.
Gurney Austin L.
Lewicki John A.
Wang Xinhao
Aeder Sean E
Casimir Jones S.C.
OncoMed Pharmaceuticals, Inc.
The Regents of the University of Michigan
LandOfFree
Compositions and methods for treating and diagnosing cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating and diagnosing cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating and diagnosing cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666603